This CRA-moderated 30-minute, intimate roundtable discussion focuses on several of the key ongoing and emerging topics in oncology and what this may mean for future pricing, access, and commercialisation of assets across Europe.
Key discussion topics include:
- Oncology combination pricing: where are we now, what challenges remain, and how do we move forward?
- mRNA oncology vaccines: how will payers approach pricing for this new technological approach to cancer treatment?
- Upcoming PD-(L)1 patent expiries: how will the loss of exclusivity for several keystone brands impact future payer decision making for new monotherapy and combination launches?
The topics discussed during the session build on several key recent CRA-produced articles found here:
- Strategies for combination therapy in oncology: Part one – Business as usual
- Strategies for combination therapy in oncology: Part two – Working with the “status quo”
- Oncology vaccines: Are they positioned for PMA success?
Panelists:
Renato Bernardini, Italy, ex-AIFA
Steve Hajioff, UK, ex-NICE
Juergen Wasem, Germany, ex-GBA
Moderator:
Aaron Everitt, Principal, Charles River Associates, London, UK
